HK1128242A1 - Indication of dosage of progesterone in the treatment of a traumatic brain injury - Google Patents

Indication of dosage of progesterone in the treatment of a traumatic brain injury

Info

Publication number
HK1128242A1
HK1128242A1 HK09107489.4A HK09107489A HK1128242A1 HK 1128242 A1 HK1128242 A1 HK 1128242A1 HK 09107489 A HK09107489 A HK 09107489A HK 1128242 A1 HK1128242 A1 HK 1128242A1
Authority
HK
Hong Kong
Prior art keywords
progesterone
dosage
indication
treatment
brain injury
Prior art date
Application number
HK09107489.4A
Other languages
English (en)
Inventor
Stuart W Hoffman
Arthur L Kellerman
Donald G Stein
David W Wright
Douglas W Lowery-North
Original Assignee
Emory University Atlanta Georgia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emory University Atlanta Georgia filed Critical Emory University Atlanta Georgia
Publication of HK1128242A1 publication Critical patent/HK1128242A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
HK09107489.4A 2005-03-24 2009-08-14 Indication of dosage of progesterone in the treatment of a traumatic brain injury HK1128242A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66472805P 2005-03-24 2005-03-24
US72966305P 2005-10-24 2005-10-24

Publications (1)

Publication Number Publication Date
HK1128242A1 true HK1128242A1 (en) 2009-10-23

Family

ID=36987966

Family Applications (3)

Application Number Title Priority Date Filing Date
HK08107067.5A HK1112579A1 (en) 2005-03-24 2008-06-25 Dosage regimen for the treatment of a traumatic brain injury with progesterone
HK08107230.7A HK1112581A1 (en) 2005-03-24 2008-06-30 Methods for the treatment of central nervous system injury via a tapered administration of progesterone
HK09107489.4A HK1128242A1 (en) 2005-03-24 2009-08-14 Indication of dosage of progesterone in the treatment of a traumatic brain injury

Family Applications Before (2)

Application Number Title Priority Date Filing Date
HK08107067.5A HK1112579A1 (en) 2005-03-24 2008-06-25 Dosage regimen for the treatment of a traumatic brain injury with progesterone
HK08107230.7A HK1112581A1 (en) 2005-03-24 2008-06-30 Methods for the treatment of central nervous system injury via a tapered administration of progesterone

Country Status (16)

Country Link
US (4) US20090221544A1 (xx)
EP (5) EP1871382B1 (xx)
JP (5) JP5295755B2 (xx)
AT (2) ATE520404T1 (xx)
AU (2) AU2006226811B2 (xx)
CA (2) CA2601715C (xx)
CY (2) CY1111478T1 (xx)
DE (1) DE602006020353D1 (xx)
DK (2) DK1868614T3 (xx)
ES (2) ES2428313T3 (xx)
HK (3) HK1112579A1 (xx)
HR (2) HRP20110198T1 (xx)
PL (2) PL1868614T3 (xx)
PT (2) PT2030622E (xx)
RS (1) RS52471B (xx)
WO (2) WO2006102596A2 (xx)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7473687B2 (en) 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ES2428313T3 (es) 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente
EP2052724A1 (en) * 2007-10-26 2009-04-29 sanofi-aventis Use of norgestimate as a selective inhibitor of TRPC3, TRPC6 and TRPC6 and TRPC7 ion channel
EP2260052A4 (en) 2008-02-26 2013-01-16 Univ Emory STEROIDANALOGA FOR NEUROPROTEKTION
MX2011003015A (es) 2008-09-18 2011-11-18 Univ Northwestern Moduladores del receptor de n-metil-d-aspartato, y usos de los mismos.
WO2010088409A2 (en) * 2009-01-30 2010-08-05 Emory University Methods of neuroprotection using neuroprotective steroids and a vitamin d
US8951968B2 (en) 2009-10-05 2015-02-10 Northwestern University Methods of treating depression and other related diseases
EP3689364A1 (en) 2010-02-08 2020-08-05 Shenzhen Evergreen Therapeutics Co., Ltd. Methods for the use of progestogen as a glucocorticoid sensitizer
US20110262502A1 (en) * 2010-02-08 2011-10-27 Prairie Pharmaceuticals LLC Pulmonary delivery of 17-hydroxyprogesterone caproate (17-hpc)
US10993879B2 (en) * 2010-02-08 2021-05-04 Shenzhen Evergreen Therapeutics Co., Ltd. Pulmonary delivery of progestogen
US10987361B2 (en) 2010-02-08 2021-04-27 Shenzhen Evergreen Therapeutics Co., Ltd. Treating auto-immune and auto-inflammatory diseases
TW201138782A (en) 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
CA2834286A1 (en) * 2011-04-27 2012-11-01 Northwestern University Methods of treating alzheimer's disease, huntington's disease, autism, and other disorders
WO2013043985A1 (en) 2011-09-23 2013-03-28 The Regents Of The University Of California Edible oils to enhance delivery of orally administered steroids
BR112014018110B1 (pt) * 2012-01-23 2022-06-07 Sage Therapeutics, Inc Composições farmacêutica aquosas formuladas para administração parenteral e uso de alopregnanolona e sulfobutiléter-b-ciclodextrina
US20130210785A1 (en) 2012-02-15 2013-08-15 Emory University Progesterone analogs and uses related thereto
EP2819650A1 (en) 2012-02-29 2015-01-07 B. Braun Melsungen AG Hormone containing emulsion comprising krill phospholipids
RU2498826C1 (ru) * 2012-05-14 2013-11-20 Федеральное государственное бюджетное учреждение науки Комплексный научно-исследовательский институт им. Х.И. Ибрагимова Российской академии наук Способ лечения больных с черепно-мозговой травмой
EP2887944B1 (en) * 2012-08-21 2021-10-06 Sage Therapeutics, Inc. Allopregnanolone for treating refractory status epilepticus
CA2892811A1 (en) 2012-11-30 2014-06-05 The Regents Of The University Of California Allopregnanolone and a sulfobutylether-b-cyclodextrin salt for the treatment of post-partum depression
BR112015018092A2 (pt) 2013-01-29 2017-07-18 Naurex Inc moduladores de receptor de nmda de espiro-lactama e usos dos mesmos
WO2014120800A1 (en) 2013-01-29 2014-08-07 Naurex, Inc. Spiro-lactam nmda receptor modulators and uses thereof
LT3514158T (lt) 2013-01-29 2023-02-10 Aptinyx Inc. Spirolaktaminiai nmda receptoriaus moduliatoriai ir jų panaudojimas
EA201591404A1 (ru) 2013-01-29 2016-01-29 Аптиникс Инк. Спиролактамные модуляторы рецептора nmda и их применение
EA032153B1 (ru) 2013-01-29 2019-04-30 Аптиникс Инк. Спиролактамные модуляторы nmda-рецептора и их применение
DK3033350T3 (da) 2013-08-12 2021-08-30 Univ Emory Progesterone fosfatanaloger og anvendelser relateret dertil
US10231979B2 (en) * 2015-08-07 2019-03-19 Indiana University Research And Technology Corporation Modulation of inflammation using progesterone metabolites
EP3426257A4 (en) 2016-03-08 2019-11-13 Sage Therapeutics, Inc. NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
MX2018014202A (es) 2016-05-19 2019-06-20 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos.
BR112019001923A2 (pt) 2016-08-01 2019-05-14 Aptinyx Inc. moduladores de nmda de espiro-lactama e métodos de sua utilização
AU2017305240B2 (en) 2016-08-01 2021-12-09 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
AU2017306152A1 (en) 2016-08-01 2019-01-31 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
PE20190500A1 (es) 2016-08-01 2019-04-10 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y uso de los mismos
MX2019001322A (es) 2016-08-01 2019-09-11 Aptinyx Inc Moduladores del receptor nmda spiro-lactam y bis-spiro-lactam y uso de los mismos.
JP7210599B2 (ja) 2018-01-31 2023-01-23 アプティニックス インコーポレイテッド スピロラクタム系ｎｍｄａ受容体修飾因子およびその使用
WO2020180424A1 (en) 2019-03-04 2020-09-10 Iocurrents, Inc. Data compression and communication using machine learning
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy
US20230190709A1 (en) * 2021-12-02 2023-06-22 MarvelBiome, Inc. Methods and uses of microbiome compositions, components, or metabolites for treating vagus nerve associated diseases, disorders, and conditions
WO2024059056A1 (en) * 2022-09-12 2024-03-21 Emory University Methods of managing traumatic brain injury

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5217085A (en) 1975-07-30 1977-02-08 Ono Pharmaceut Co Ltd Method of quantitative determination of free fatty acids in serum usin g fatty acid activating enzymes
US4404366A (en) * 1980-05-06 1983-09-13 Miles Laboratories, Inc. Beta-galactosyl-umbelliferone-labeled hapten conjugates
US4369250A (en) 1981-07-31 1983-01-18 Sherwood Medical Industries Inc. Fatty acid determination
USRE35517E (en) * 1987-08-25 1997-05-20 University Of Southern California Method, compositions, and compounds for modulating brain excitability
US5120723A (en) * 1987-08-25 1992-06-09 University Of Southern California Method, compositions, and compounds for modulating brain excitability
AU609927B2 (en) 1987-08-25 1991-05-09 Kelvin W. Gee Compositions and methods for alleviating stress, anxiety and seizure activity
US5232917A (en) * 1987-08-25 1993-08-03 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the GABA receptor by members of the androstane and pregnane series
US5512429A (en) 1989-09-19 1996-04-30 British Technology Group Limited Assay for enzyme activity
GB9105707D0 (en) 1991-03-18 1991-05-01 Wilton David C Assay
US5114388A (en) * 1991-07-26 1992-05-19 True Fitness Technology, Inc. Stair simulator exerciser with adjustable incline
US5212167A (en) * 1991-09-12 1993-05-18 Trustees Of Boston University Modulation of receptor-mediated ion transport
US5206415A (en) * 1991-12-20 1993-04-27 Washington University Tricyclic steroid analogs
US5776923A (en) * 1993-01-19 1998-07-07 Endorecherche, Inc. Method of treating or preventing osteoporosis by adminstering dehydropiandrosterone
AU5855794A (en) * 1993-01-19 1994-08-15 Endorecherche Inc. Therapeutic uses and delivery systems of dehydroepiandrosterone
DE4311870C2 (de) 1993-04-10 1998-07-30 Altramed Holdings Ltd Verwendung eines Anti-Östrigens zur Therapie und Prophylaxe von Demenz-Erkrankungen
WO1995005826A1 (en) * 1993-08-20 1995-03-02 Jackson Meyer B Method for regulating neuropeptide hormone secretion
US5763431A (en) * 1993-08-20 1998-06-09 Jackson; Meyer B. Method for regulating neuropeptide hormone secretion
US5939545A (en) * 1994-02-14 1999-08-17 Cocensys, Inc. Method, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US5633011A (en) * 1994-08-04 1997-05-27 Alza Corporation Progesterone replacement therapy
FR2727117A1 (fr) * 1994-11-18 1996-05-24 Geffard Michel Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun
US5767117A (en) * 1994-11-18 1998-06-16 The General Hospital Corporation Method for treating vascular headaches
US5741899A (en) * 1995-02-02 1998-04-21 Cell Genesys, Inc. Chimeric receptors comprising janus kinase for regulating cellular pro liferation
DE69634039T2 (de) * 1995-06-06 2005-12-08 Euro-Celtique S.A. Steroidderivate der Androstan- und der Pregnanreihe
US5942241A (en) * 1995-06-09 1999-08-24 Euro-Celtique, S.A. Formulations and methods for providing prolonged local anesthesia
US5888996A (en) * 1995-07-26 1999-03-30 Trustees Of Boston University Inhibition of NMDA receptor activity and modulation of glutamate-mediated synaptic activity
AU3136897A (en) 1996-05-22 1997-12-09 Diversified Pharmaceuticals, Inc. Compositions, methods and devices for the transdermal delivery of drugs
US5763492A (en) * 1996-10-01 1998-06-09 Duguesne University Of The Holy Ghost Methods for effecting memory enhancement mediated by non-steroidal sulfatase inhibitors
DE69809223T2 (de) 1997-05-02 2003-07-24 Wyeth Corp 5-alpha-pregnan-3-beta-ol-20-one 3-sulfate für di behandlung von tumoren und zns krankheiten
US6245757B1 (en) * 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6174547B1 (en) * 1999-07-14 2001-01-16 Alza Corporation Dosage form comprising liquid formulation
US6268223B1 (en) 1999-08-27 2001-07-31 Viatech Imagin, Llc Assay for detecting damage to the central nervous system
US20020072509A1 (en) * 2000-10-11 2002-06-13 Stein Donald Gerald Methods for the treatment of a traumatic central nervous system injury
US7473687B2 (en) * 2005-03-24 2009-01-06 Emory University Methods for the treatment of a traumatic central nervous system injury
ES2428313T3 (es) * 2005-03-24 2013-11-07 Emory University Métodos para el tratamiento de lesiones del sistema nervioso central mediante un protocolo de administración decreciente

Also Published As

Publication number Publication date
US20090221544A1 (en) 2009-09-03
PL2030622T3 (pl) 2011-07-29
ATE499104T1 (de) 2011-03-15
DE602006020353D1 (de) 2011-04-07
JP2014055183A (ja) 2014-03-27
WO2006102644A9 (en) 2006-11-23
HK1112579A1 (en) 2008-09-12
EP1871382A2 (en) 2008-01-02
ES2392454T3 (es) 2012-12-10
EP1868614B1 (en) 2012-08-08
JP2011225629A (ja) 2011-11-10
US20090325920A1 (en) 2009-12-31
PT2030622E (pt) 2011-06-02
WO2006102596A3 (en) 2007-01-18
ATE520404T1 (de) 2011-09-15
AU2006226811A1 (en) 2006-09-28
CY1111478T1 (el) 2015-08-05
DK2030622T3 (da) 2011-05-02
PT1868614E (pt) 2012-11-23
HRP20110198T1 (hr) 2011-04-30
WO2006102644A3 (en) 2007-03-01
EP2431042B1 (en) 2013-06-26
WO2006102596A2 (en) 2006-09-28
CY1113253T1 (el) 2016-04-13
US8614203B2 (en) 2013-12-24
CA2602950A1 (en) 2006-09-28
JP5394059B2 (ja) 2014-01-22
CA2601715A1 (en) 2006-09-28
DK1868614T3 (da) 2012-11-12
JP5496407B2 (ja) 2014-05-21
JP2008534512A (ja) 2008-08-28
AU2006226774A1 (en) 2006-09-28
HRP20120688T1 (hr) 2012-09-30
EP2030622A1 (en) 2009-03-04
US20120289491A1 (en) 2012-11-15
CA2601715C (en) 2012-10-16
JP2013234191A (ja) 2013-11-21
EP2431042A1 (en) 2012-03-21
WO2006102644A2 (en) 2006-09-28
ES2428313T3 (es) 2013-11-07
HK1112581A1 (en) 2008-09-12
EP1871382B1 (en) 2011-08-17
AU2006226811B2 (en) 2010-11-25
RS52471B (en) 2013-02-28
EP1868614A2 (en) 2007-12-26
EP2494976A1 (en) 2012-09-05
EP2030622B1 (en) 2011-02-23
PL1868614T3 (pl) 2013-01-31
JP5295755B2 (ja) 2013-09-18
AU2006226774B2 (en) 2010-12-02
CA2602950C (en) 2012-10-30
US20120245133A1 (en) 2012-09-27
JP2008534515A (ja) 2008-08-28

Similar Documents

Publication Publication Date Title
HK1128242A1 (en) Indication of dosage of progesterone in the treatment of a traumatic brain injury
WO2008039898A3 (en) Methods for the treatment of a traumatic central nervous system injury
EP1648385A4 (en) SYSTEM AND METHOD FOR THE PHOTODYNAMIC TREATMENT OF COMBUSTIONS, WOUNDS AND RELATED SKIN DISEASES
IL225192A (en) Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury
WO2012106444A3 (en) Methods, devices and systems for treating insomnia by inducing frontal cerebral hypothermia
HK1116202A1 (en) Means and methods for the treatment of tumorous diseases
PL1913947T3 (pl) Terapia skojarzona do leczenia raka
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
HK1095285A1 (en) Benzamidine derivatives for treatment and prevention of mucositis
IL163752A0 (en) Use of epothilones in the treatment of brain diseases associated with proliferative processes
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
WO2018060528A3 (en) Therapeutic protein
Axelrod et al. The combination of entospletinib and vincristine demonstrates synergistic activity in a broad panel of hematological cancer cell lines and anti-tumor efficacy in a DLBCL xenograft model
WO2011071981A3 (en) Anti-cytomegalovirus activity of artemisinin-derived dimers
WO2006096458A3 (en) Treatment of hyperproliferative diseases with anthraquinones
WO2017197249A3 (en) METHODS OF TREATING HYPER-BILIRUBINEMIA USING STANNSOPORFIN AND PHOTOTHERAPY
Fourianalistyawati et al. The Effectiveness of Mindfulness Technique to Decrease Pain in University Students
GB202218314D0 (en) Vitamin a for use in the treatment of traumatic brain injury
Chefranova et al. Efficacy of mexidol in the combination with thrombolytic therapy in patients with ischemic stroke
GB202011154D0 (en) Use of cannabidiol in the treatment of seizures associated with encephaltis
GB202011126D0 (en) Use of cannabidiol in the treatment of sezures associated with mutifocal epilepsy
Peter Celecoxib/thalidomide/temozolomide
UA77025U (ru) Способ лечения больных с черепно-мозговой травмой

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190326